ArticleLeukemia research reports2026
Therapeutic outcomes of acute promyelocytic leukemia in children.
Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In children, acute promyelocytic leukemia is a distinct and underreported entity. The objective of our study is to report the therapeutic outcomes of APL in the pediatric population. Methods: This was a descriptive, retrospective, single-center study including 30 patients diagnosed with APL over an 18-year period. Patients were treated in the Hematology Department of Aziza Othmana Hospital in Tunis. Results: The median age at diagnosis was 11 years, with a sex ratio of 0.87. Half of the patients were classified as high-risk. Post-induction cytologic remission was achieved in 86.6 % of patients. There were five cases of relapse, 60 % of which were early relapses. The 5-year overall survival rate was 70.6 %.The 5-year event-free survival rate was 72 %. The 5-year relapse-free survival rate was 80 %. Conclusion: Although our results were satisfactory, they revealed a poor prognosis for relapsed patients. A larger study focusing on relapse characteristics is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.